16 September 2026 editorial review · Item
CRISPR Therapeutics CTX213 (CTX211 programme successor): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
-
Disposition: corrected after additional opening-summary and ranking QA; current item
lastReviewed: 2026-09-16. -
Claim check: CTX211's five-participant trial remains terminated. Sponsor-reported detectable C-peptide at 12 months is unquantified; successor CTX213 is preclinical. CAR-T immune-evasion papers provide platform context, not CTX211 islet outcomes. Protocol exclusion of chronic immunosuppression does not document every recipient's full treatment course.
-
Registry NCT05565248: TERMINATED; updated 2026-05-07; enrollment 5 (ACTUAL); primary completion 2025-08-08 (ACTUAL); results not posted in retrieved record.
-
Registry NCT05210530: COMPLETED; updated 2023-06-26; enrollment 7 (ACTUAL); primary completion 2023-01-19 (ACTUAL); results not posted in retrieved record.
-
Primary publication/regulatory sources checked or consulted: s41467-023-37785-2; j.stem.2025.07.009.
-
Programme/sponsor/conference source boundary: CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones (manufacturer); CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results (manufacturer); CRISPR Therapeutics pipeline — CTX213 (Regenerative Medicine) (manufacturer).
-
Additional correction: public name and scoring scope now identify current CTX213; evidence badge preclinical, all criteria rebuilt around successor-specific uncertainty. Removed predecessor age/access fields, inferred all-five drug-free treatment course, and inherited device-retrieval safety benefit. Stage 0 unchanged.
-
Newly inspected 3 August 2026 company presentation, slide 41 adds sponsor-reported CTX211 no serious adverse events or adverse events of special interest, 12-month C-peptide and histologic insulin-cell survival despite device fibrosis and immune infiltration. This supersedes the earlier ledger’s narrow description of one unquantified press-release sentence; it is not peer-reviewed full clinical results, nor CTX213 human evidence. CTX213 rat findings are preclinical.
-
3 August Q2 update supports current preclinical status. CTX213 registry name search repeated 16 September returned 0; no worldwide absence inferred.